Latest Conference Articles

PEDFIC data at NASPGHAN 2024 show mild, transient diarrhea events with odevixibat for cholestatic pruritus in PFIC, resolving in most cases.

A 10-year study reveals a surge in water bead injuries in young children, with an increase in cases requiring surgical intervention for bowel obstructions.

At NASPGHAN 2024, Collen told HCPLive the promising early data of advanced combination therapy for pediatric refractory IBD although hurdles exist.

Meta-analysis of 30 studies highlights serum markers as prognostic tools for liver survival post-portoenterostomy in biliary atresia.

HCPLive spoke to Collen at NASPGHAN 2024 about early research on environmental exposures prevalent in children with Crohn’s Disease.

Linaclotide trial shows effective constipation relief for pediatric patients with neurodevelopmental disorders, with high treatment adherence and safety profile.

New data from the UNOS database presented at NASPGHAN 2024 details characteristics and outcomes of pediatric liver transplant patients receiving machine perfused organs.

NASPGHAN 2024 data suggests children and adolescents with a history of COVID-19 were twice as likely to develop IBS during the follow-up period.

At NASPGHAN 2024, Sadaka shared results of a study demonstrating the factors associated with a longer hospital stay for children with gastroparesis.

HCPLive spoke to Sadaka at NASPHAN 2024 about the increase in hospital admissions among children with gastroparesis after the COVID-19 pandemic.

At NASPGHAN 2024, HCPLive spoke to Shameem about his study on inpatient outcomes of pediatric patients with IBD and GAD vs patients without GAD.

Although children on baclofen had numerically greater improvements in rumination syndrome symptoms than those on placebo, the group difference was insignificant.

MASEF score seemed to be sensitive and effective in detecting at-risk MASH in 2 abstracts presented at the ACG 2024 Meeting.

Phase 3, 3b, and 4 clinical trials will provide long-term insight into the use of elafibranor in different PBC patient populations and real-world settings.

New PRO data from the INTEGUMENT-1 and –2 studies were presented at the ACAAI 2024 Meeting.

This interview from Fall Clinical highlights the broader implications of the phase 3 data resulting from the ARRECTOR trial on roflumilast foam for those with psoriasis.

This interview following Fall Clinical highlights new phase 3 data on patient-reported outcomes from the ARRECTOR study evaluating roflumilast foam for psoriasis.

This conference review highlights several of the most notable stories and recent data covered by HCPLive at the Fall Clinical Dermatology Conference.

Mice models had improved disease phenotype and high transduction of PS-002 gene therapy.

This interview from Fall Clinical featured a discussion of new findings on upadacitinib (Rinvoq) for patients with atopic dermatitis.

Yee discussed research she is conducting into gFSGS and nephrotic syndrome, presented at ASN Kidney Week.

These data suggest brodalumab’s safety profile is consistent with findings from long-term clinical trials, with no new occurrences of suicide and a low rate of fungal infection.

Abdellatif discussed the high prevalence of gout in patients with chronic kidney disease and the importance of screening and early treatment.

Popov reviews findings from her late-breaking presentation at ACG 2024 suggesting GLP-1 RAs may not need to be held prior to upper endoscopy.

Rao explains the comparative effectiveness of biofeedback and dextranomer injections for treating fecal incontinence.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on updates related to atrasentan.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on felzartamab.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, particularly data on long-term use of Nefecon.